By admin 
On Wednesday, a high-stakes meeting of the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee culminated in a resounding 9-to-3 vote against the effectiveness of deramiocel, a cell therapy developed by Capricor Therapeutics for the treatment of Duchenne muscular dystrophy (DMD). The committee’s decision focused specifically on the drug’s ability to treat DMD-related cardiomyopathy, a progressive heart condition that remains the leading cause of death for patients with this genetic disorder. This marks a critical setback for Capricor, which has spent years attempting to bring deramiocel to market as a potential life-extending therapy.
Duchenne muscular dystrophy is a devastating X-linked recessive disorder characterized by the absence of dystrophin, a protein vital for muscle integrity. While much of the therapeutic focus in the DMD space has historically centered on skeletal muscle function and mobility, the cardiac implications of the disease are often the most lethal. As patients survive longer due to improved respiratory care, the onset of cardiomyopathy—where the heart muscle weakens and fails—has become the primary clinical challenge. Capricor’s deramiocel, also known as CAP-1002, consists of cardiosphere-derived cells (CDCs) intended to reduce inflammation and promote tissue regeneration in the heart.
The advisory panel’s skepticism was rooted in a contentious history between the agency and the manufacturer. Last year, the FDA issued a Complete Response Letter (CRL) declining to approve the therapy, citing a lack of robust efficacy data. At that time, the agency requested additional clinical evidence to support the drug’s purported benefits. During yesterday’s marathon session, however, FDA reviewers expressed deep concerns regarding the integrity of the data provided from the HOPE-2 and HOPE-3 clinical trials. The agency’s primary grievance centered on Capricor’s handling of its statistical analysis plan. According to FDA representatives, the company made substantial, mid-study modifications to how it interpreted the data, a move that the agency argued "degraded the robustness" of the results.
In the world of clinical research, the statistical analysis plan is considered the blueprint for objectivity; changing it after data collection has begun can lead to "p-hacking" or the artificial inflation of positive outcomes. The FDA’s briefing documents highlighted that these changes made even the seemingly positive trends in cardiac function difficult to interpret with any scientific certainty. While patient advocates and families provided emotional testimony during the public hearing, describing the desperate need for cardiac-specific treatments, the majority of the panel remained unconvinced that the clinical trials met the "substantial evidence" threshold required for regulatory approval. The 9-to-3 vote serves as a non-binding but influential recommendation to the FDA, which will make its final decision later this year. If the agency follows the panel’s lead, Capricor may be forced to conduct entirely new, more rigorous trials, potentially delaying the drug’s availability by several more years.
Simultaneously, the digital health landscape is facing its own reckoning. The Federal Trade Commission, in coordination with the states of Utah and California, has filed a comprehensive lawsuit against Hims & Hers Health, Inc., alleging a pattern of deceptive business practices and the mishandling of sensitive consumer health data. This lawsuit represents a significant escalation in the FTC’s ongoing crackdown on the "Direct-to-Consumer" (DTC) healthcare industry, which has grown exponentially since the COVID-19 pandemic.
Hims & Hers, a platform known for its aggressive marketing of treatments for hair loss, erectile dysfunction, and mental health, is accused of misleading its users regarding the privacy of their medical information. The FTC alleges that while the company promised patients that their health histories and treatment plans would remain confidential, it was simultaneously sharing sensitive data with third-party advertising platforms, including Meta (Facebook) and Google, to facilitate targeted marketing campaigns. This practice, often referred to as "pixel tracking," has become a flashpoint for privacy advocates who argue that health platforms should be held to the same standards as traditional medical providers, even if they do not technically fall under the jurisdiction of the Health Insurance Portability and Accountability Act (HIPAA).
Beyond data privacy, the lawsuit takes aim at the company’s subscription-based business model. The FTC and state attorneys general allege that Hims & Hers employs "dark patterns"—manipulative user interface designs—to trick consumers into recurring billing cycles. According to the complaint, when patients fill out medical intake forms, they are often unknowingly signing up for subscriptions that renew automatically. The lawsuit further claims that the company makes the cancellation process unnecessarily "onerous and confusing," preventing users from opting out of services they no longer want or need.
Perhaps most concerning to medical ethics experts is the allegation that Hims & Hers does not provide patients with a meaningful opportunity to review a provider’s recommended treatment plan or provide informed consent before being billed. In the traditional medical model, a diagnosis and prescription are followed by a consultation where risks and benefits are discussed. The FTC alleges that Hims & Hers streamlines this process to the point of negligence, prioritizing transaction speed over patient agency. This "frictionless" approach to medicine, while convenient for the consumer, is now being legally challenged as a deceptive trade practice.
The legal action against Hims & Hers follows similar enforcement moves against other digital health giants like BetterHelp and GoodRx. It signals a shift in the regulatory environment where the FTC is increasingly acting as a "health privacy regulator" in the absence of a comprehensive federal privacy law. For Hims & Hers, the lawsuit could result in massive fines and a court-ordered overhaul of its data-sharing and billing practices. For the broader industry, it serves as a warning that the "move fast and break things" ethos of Silicon Valley is no longer compatible with the sensitive nature of healthcare delivery.
The convergence of these two stories—the FDA’s rejection of Capricor’s data and the FTC’s pursuit of Hims & Hers—highlights a broader theme in 2026: the reassertion of institutional oversight. In the pharmaceutical sector, the FDA is signaling that it will not lower the bar for efficacy, even for rare diseases with high unmet needs, if the underlying data is statistically compromised. In the digital health sector, the FTC is signaling that "convenience" cannot come at the expense of consumer privacy and transparent commerce.
As the day unfolds, market analysts expect significant volatility for both Capricor and Hims & Hers. Capricor’s stock was halted in pre-market trading following the panel’s vote, with investors bracing for a potential collapse in valuation. Meanwhile, Hims & Hers faces a reputational crisis that could alienate its core user base of younger, tech-savvy consumers who are increasingly sensitive to how their data is harvested.
The Pharmalot campus will continue to monitor these developments closely. For the families of those with Duchenne muscular dystrophy, the FDA panel’s decision is a heartbreaking setback in the quest for a longer life. For the millions of Americans using telehealth apps, the FTC’s lawsuit is a stark reminder that in the digital age, your most intimate health secrets are often the most valuable commodity. As we finish our English breakfast tea and prepare for the afternoon’s briefings, it is clear that the intersection of medicine, data, and law has never been more fraught with complexity. We remain committed to bringing you the latest analysis as these stories evolve. Stay tuned for further updates on the regulatory path for deramiocel and the legal proceedings in the Hims & Hers case.
